Andrew J Patterson

US Patent:

6932314, Aug 23, 2005

Filed:

Jan 15, 2004

Appl. No.:

10/758690

Inventors:

Andrew W. Patterson - Falls Church VA, US
Steven Snyder - Olney MD, US
Magdalena Kotek - Raleigh NC, US

Assignee:

Beijing Trade Exchange, Inc. - Washington DC

International Classification:

A47B091/00

US Classification:

24834611, 16 31 A

Abstract:

Sleeves for use in systems for supporting platform-like objects on casters and posts and described. The sleeves support caster-and-post junctions and inhibit deformation of the stems of the casters and the ends of posts in directions radially outward from the longitudinal axes of the stems and posts.

US Patent:

20090318556, Dec 24, 2009

Filed:

May 15, 2008

Appl. No.:

12/121208

Inventors:

Jeffrey R. Idle - Roztoky, CZ
Frank J. Gonzalez - Bethesda MD, US
John B. Tyburski - Gaithersburg MD, US
Kristopher W. Krausz - Bethesda MD, US
Andrew David Patterson - Montgomery Village MD, US

International Classification:

A61K 31/195
C07C 63/06
C07C 229/02
C07H 19/06
C07C 309/03
C07D 473/04
C07H 19/16
G01N 33/48
G01N 33/68
C12Q 1/02
G01N 33/00
A61P 43/00
G01N 27/447

US Classification:

514562, 562426, 562553, 536 2853, 562104, 544267, 536 2721, 536 285, 436 98, 436 94, 436120, 436 89, 435 29, 422 681, 536 284, 204461

Abstract:

Disclosed herein are biomarkers for determining gamma radiation exposure by an animal or human. The biomarkers include 3-hydroxy-2-methylbenzoic acid 3-O-sulfate, N-hexanoylglycine, β-thymidine, taurine, xanthine, xanthosine, 2′-deoxyuridine, 2′-deoxycytidine, 2′-deoxyxanthosine, or any salt, ion, or combination thereof. Also disclosed are methods for determining gamma radiation exposure by an animal or human, which include the step of measuring the amount of one or more biomarkers specific to gamma radiation in the biological fluid and correlating the amount of said biomarkers to the amount of gamma radiation exposure by the animal or human. Systems for determining gamma radiation exposure by an animal or human and methods of treating an animal or human for gamma radiation exposure are also disclosed.

US Patent:

20190369102, Dec 5, 2019

Filed:

May 14, 2019

Appl. No.:

16/412003

Inventors:

- Bethesda MD, US
Ewy MATHE - Bethesda MD, US
Andrew D. PATTERSON - Bethesda MD, US
Curtis Craig HARRIS - Bethesda MD, US
Frank GONZALEZ - Bethesda MD, US
Kristopher KRAUSZ - Bethesda MD, US
Soumen MANNA - Bethesda MD, US

International Classification:

G01N 33/574

Abstract:

The present invention provides methods and materials for diagnosing cancer in an individual using a tissue, blood or urine sample from the patient. Specifically, the disclosed method comprises determining the level of one or more metabolite selected from the group consisting of creatine riboside, metabolite 561+, cortisol sulfate and N-acetylneuraminic acid. The present invention also provides a method for determining the prognosis of a cancer patient by determining the level of one or more metabolite selected from the group consisting of creatine riboside, metabolite 561+, cortisol sulfate and N-acetylneuraminic acid. Also provided are kits for detecting cancer or determining the prognosis of a cancer patient.

US Patent:

20170152283, Jun 1, 2017

Filed:

Dec 6, 2016

Appl. No.:

15/371032

Inventors:

- Bethesda MD, US
- University Park PA, US
Cen Xie - Rockville MD, US
Andrew D. Patterson - State College PA, US
Fei Li - Rockville MD, US
James B. Mitchell - Damascus MD, US
Shantu Amin - Union City NJ, US
Dhimant Desai - Mechanicsburg PA, US

Assignee:

The United States of America, as represented by the Secretary, Dept. of Health and Human Services - Bethesda MD
The Penn State Research Foundation - University Park PA

International Classification:

C07J 41/00
C07J 31/00

Abstract:

Disclosed are inhibitors of the farnesoid X receptor, for example of formula (I), wherein R, R, R, X, Y, Z, m, and n are as defined herein, which are useful in treating or preventing obesity, type 2 diabetes/insulin resistance and non-alcoholic fatty liver disease in a mammal in need thereof. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the invention, a method of method of inhibiting a farnesoid X receptor in a mammal, and a method of treating or preventing obesity in a mammal.

US Patent:

20160169899, Jun 16, 2016

Filed:

Jul 11, 2014

Appl. No.:

14/903706

Inventors:

- Rockville MD, US
Ewy MATHE - Bethesda MD, US
Andrew D. PATTERSON - Bethesda MD, US
Curtis Craig HARRIS - Bethesda MD, US
Frank GONZALEZ - Bethesda MD, US
Kristopher KRAUSZ - Bethesda MD, US
Soumen MANN - Bethesda MD, US

International Classification:

G01N 33/574

Abstract:

The present invention provides methods and materials for diagnosing cancer in an individual using a tissue, blood or urine sample from the patient. Specifically, the disclosed method comprises determining the level of one or more metabolite selected from the group consisting of creatine riboside, metabolite 561+, Cortisol sulfate and N-acetylneuraminic acid. The present invention also provides a method for determining the prognosis of a cancer patient by determining the level of one or more metabolite selected from the group consisting of creatine riboside, metabolite 561+, Cortisol sulfate and N-acetylneuraminic acid. Also provided are kits for detecting cancer or determining the prognosis of a cancer patient.

US Patent:

20160159851, Jun 9, 2016

Filed:

Aug 1, 2014

Appl. No.:

14/909263

Inventors:

- Bethesda MD, US
- University Park PA, US
Cen Xie - Rockville MD, US
Andrew D. Patterson - State College PA, US
Fei Li - Rockville MD, US
James B. Mitchell - Damascus MD, US
Shantu Amin - Union City NJ, US
Dhimant Desai - Mechanicsburg PA, US

Assignee:

The United Sates of America, as represented by the Secretary, Department of Health and Human Service - Bethesda MD
The Penn State Research Foundation - University Park PA

International Classification:

C07J 41/00

Abstract:

Disclosed are inhibitors of the farnesoid X receptor, for example of formula (I), wherein R, R, R, X, Y, Z, m, and n are as defined herein, which are useful in treating or preventing obesity, type 2 diabetes/insulin resistance and non alcoholic fatty liver disease in a mammal in need thereof. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least Cone compound of the invention, a method of method of inhibiting a farnesoid X receptor in a mammal, and a method of treating or preventing obesity in a mammal.

US Patent:

20140344708, Nov 20, 2014

Filed:

Mar 14, 2014

Appl. No.:

14/210550

Inventors:

Michael Carr - Chantilly VA, US
Andrew Patterson - Burke VA, US
Jacqueline Meriwether - Fairfax VA, US
Robert McWaters - Harvard MA, US

International Classification:

G06F 3/0481
G06F 3/0484

US Classification:

715751

Abstract:

A method of capturing business intelligence requirements includes establishing a graphical object definition interface, receiving user input through this interface to define various requirements objects, and storing the user-defined requirements objects in an object library. A graphical business intelligence outputs interface can also be established, such that users can provide input to define business intelligence outputs, each of which includes at least one requirements object from the object library expressed in reports and/or dashboards. Systems for practicing this and related methods are also disclosed.